Table II.
Adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE) v. 3.0 (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf)
| Adverse Event | Events related to fenretinide and rituximab (any grade) |
Grade 3 Events | Grade 4 Events | |||
|---|---|---|---|---|---|---|
| Patients (n) | % | Patients (n) | % | Patients (n) | % | |
| Night blindness | 18 | 56 | 1 | 3 | 0 | 0 |
| Eye disorders, other * | 17 | 53 | 0 | 0 | 0 | 0 |
| Maculopapular rash | 12 | 38 | 3 | 9 | 0 | 0 |
| Lymphocyte count decreased | 8 | 25 | 1 | 3 | 0 | 0 |
| Photosensitivity | 8 | 25 | 0 | 0 | 0 | 0 |
| Diarrhoea | 7 | 22 | 1 | 3 | 0 | 0 |
| Platelet count decreased | 7 | 22 | 0 | 0 | 0 | 0 |
| Neutrophil count decreased | 6 | 19 | 1 | 3 | 2 | 6 |
| White blood cell decreased | 6 | 19 | 0 | 0 | 1 | 3 |
| Anaemia | 5 | 16 | 0 | 0 | 0 | 0 |
| Aspartate transaminase increased | 5 | 16 | 0 | 0 | 0 | 0 |
| Hypocellular bone marrow | 5 | 16 | 1 | 3 | 0 | 0 |
| Dry skin | 5 | 16 | 0 | 0 | 0 | 0 |
*
Yellowing/discoloration of lights, altered colour perception, peripheral vision changes, blind spot in visual field